The question about whether the deliberate selection of antipsychotics (prolactin raising vs. prolactin sparing; weight gaining, or weight sparing) in postmenopausal women with schizophrenia makes a difference to outcome remains essentially unanswered, although the analysis by Goldstein et al. [16] suggests that there may be no difference. The gene discussed is PRL; the disease is schizophrenia.